- Home
- ELVN vs DAVE Comparison
ELVN vs DAVE Comparison
Compare ELVN & DAVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- DAVE
- Stock Information
- Founded
- ELVN 2016
- DAVE 2017
- Country
- ELVN United States
- DAVE United States
- Employees
- ELVN N/A
- DAVE N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- DAVE Retail: Computer Software & Peripheral Equipment
- Sector
- ELVN Health Care
- DAVE Technology
- Exchange
- ELVN Nasdaq
- DAVE Nasdaq
- Market Cap
- ELVN 1.0B
- DAVE 1.2B
- IPO Year
- ELVN 2020
- DAVE N/A
- Fundamental
- Price
- ELVN $22.35
- DAVE $99.08
- Analyst Decision
- ELVN Strong Buy
- DAVE Strong Buy
- Analyst Count
- ELVN 5
- DAVE 7
- Target Price
- ELVN $37.80
- DAVE $99.86
- AVG Volume (30 Days)
- ELVN 269.1K
- DAVE 353.8K
- Earning Date
- ELVN 03-13-2025
- DAVE 03-04-2025
- Dividend Yield
- ELVN N/A
- DAVE N/A
- EPS Growth
- ELVN N/A
- DAVE N/A
- EPS
- ELVN N/A
- DAVE 3.12
- Revenue
- ELVN N/A
- DAVE $319,355,000.00
- Revenue This Year
- ELVN N/A
- DAVE $34.76
- Revenue Next Year
- ELVN N/A
- DAVE $19.55
- P/E Ratio
- ELVN N/A
- DAVE $31.68
- Revenue Growth
- ELVN N/A
- DAVE 30.00
- 52 Week Low
- ELVN $10.90
- DAVE $18.50
- 52 Week High
- ELVN $30.03
- DAVE $108.50
- Technical
- Relative Strength Index (RSI)
- ELVN 47.03
- DAVE 59.27
- Support Level
- ELVN $20.40
- DAVE $86.63
- Resistance Level
- ELVN $22.42
- DAVE $103.30
- Average True Range (ATR)
- ELVN 1.25
- DAVE 6.29
- MACD
- ELVN 0.06
- DAVE 0.50
- Stochastic Oscillator
- ELVN 59.59
- DAVE 79.03
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit, and finding side gigs.